New Hampshire House Bill HB272

New Hampshire 2022 Regular Session

• Introduced: 1/9/21
• Refer: 1/9/21
• Report Pass: 2/18/21
• Engrossed: 4/7/21
• Refer: 4/7/21
• Refer: 4/14/21
• Refer: 4/22/21
• Report Pass: 12/16/21

Caption

Relative to the labeling and sale of hemp products containing CBD.

Impact

The bill modifies existing regulations by defining parameters around the production and marketing of food products that contain hemp or CBD. It explicitly states that these products will not be labeled as adulterated or misbranded based solely on the inclusion of hemp or CBD. The goal of this policy is to create a more favorable environment for the sale and distribution of hemp-derived products, which could stimulate market growth and provide consumers with more options. Additionally, the bill mandates strict testing and labeling requirements to ensure consumer safety and product transparency.

Summary

House Bill 272, also known as HB272, addresses the regulation of hemp products containing cannabidiol (CBD). The bill facilitates the sale of CBD products derived from hemp by establishing guidelines for their registration and inspection. Under the proposed legislation, manufacturers are required to annually register products containing CBD with the Department of Health and Human Services, ensuring compliance with state laws concerning the sale of hemp derivatives. Furthermore, a special fund known as the Cannabidiol Program Fund is created to support the operational needs associated with these regulations.

Conclusion

Overall, HB272 signifies a significant step towards the formal regulation of hemp products within the state. While it aims to provide clarity and encourage economic activity, the discussions around its implementation suggest that stakeholders will need to monitor ongoing developments closely to address regulatory challenges and ensure consumer safety.

Contention

Although proponents argue that HB272 will boost economic growth by legitimizing the hemp industry and promoting local manufacturing, critics express concern about the potential risks. Some worry that insufficient regulation could result in unsafe or misleading products entering the market. A point of contention involves the requirement for all CBD products to be manufactured in New Hampshire, which could limit national and international trade opportunities. Furthermore, the bill’s provisions around labeling and claims made by manufacturers necessitate careful oversight to prevent misleading information regarding health benefits.